Dr. Nielsen Discusses the PAM50 Assay

Torsten O. Nielsen, MD, PhD, FRCPC
Published Online: Friday, Nov 08, 2013

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.

Most molecular tests, Nielsen says, are very specific for the patient sets from which they were derived and the type of treatment that patients receive. PAM50 is different because it is a biological test that identifies the intrinsic subtypes of breast cancer, Nielsen says. The PAM50 assay is likely to provide relevant information in different types of breast cancer and in different treatment settings.

Nielsen says there are currently clinical trials that are comparing PAM50 with other tests and applying PAM50 to other types of specimens.
Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.

Most molecular tests, Nielsen says, are very specific for the patient sets from which they were derived and the type of treatment that patients receive. PAM50 is different because it is a biological test that identifies the intrinsic subtypes of breast cancer, Nielsen says. The PAM50 assay is likely to provide relevant information in different types of breast cancer and in different treatment settings.

Nielsen says there are currently clinical trials that are comparing PAM50 with other tests and applying PAM50 to other types of specimens.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 20, 20162.5
Oncology Consultations®: Integrating Molecular Testing into the Breast Cancer Treatment ParadigmSep 28, 20162.0